No products in the cart.
Pre-made Naratuximab benchmark antibody ( Whole mAb ADC, anti-CD37 therapeutic antibody, Anti-GP52-40/TSPAN26 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-364
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Naratuximab biosimilar, Whole mAb ADC, Anti-CD37 Antibody: Anti-GP52-40/TSPAN26 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Naratuximab emtansine | IMGN529 (K7153A) | Debio 1562 | Drug Description. … The investigational drug is in clinical trials for the potential treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, B-Cell Lymphomas. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.
| Products Name (INN Index) | Pre-Made Naratuximab biosimilar, Whole mAb ADC, Anti-CD37 Antibody: Anti-GP52-40/TSPAN26 therapeutic antibody |
|---|---|
| INN Name | Naratuximab |
| Target | CD37 |
| Format | Whole mAb ADC |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | ImmunoGen,Chronic lymphocytic leukaemia |
| Conditions Approved | NA |
| Conditions Active | Diffuse large B cell lymphoma,Non-Hodgkin's lymphoma |
| Conditions Discontinued | Chronic lymphocytic leukaemia |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD37 |
| Package |
Previous slide
Next slide
